Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy: The experience in the management of 300 consecutive patients

Journal of B.U.ON.

Volumn 10, Issue 2, 2005, Pages 195-200

  Argirović, Djordje ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Chemotherapy; Nonseminomatous testicular tumors; Retroperitoneal lymphadenectomy; Seminomatous testicular tumors; Stage A; Surveillance

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; ONDANSETRON; TUMOR MARKER; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GERM CELL TUMOR; HIGH RISK PATIENT; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PARAAORTIC LYMPH NODE; PATIENT MONITORING; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; SEMINOMA; SIDE EFFECT; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME;

EID: 24944444063     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Heidenreich A, Sesterhenn IA, Mostofi FK et al. Prognostic risk factors that identify patients with clinical stage I non-seminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998; 83: 1002-1011.
2. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
3. Argirovic DJ, Radosevic-Jelic LJ. Carboplatin (CBDCA) monochemotherapy (MCHT) versus radiotherapy (Rtx) in clinical stage A (CS-A) seminomatous testicular tumors (STT): the two institutions experience. BJU Int 2004 (Suppl); 34: 115 (abstr).
4. Chung P, Parker C, Panzarella T et al. Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol 2002; 9: 1637-1640.
5. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000; 163: 1788-1792.
6. Willians SD, Stablein DM, Einhorn L et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317: 1433-1438.
7. Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21: 1505-1512.
8. Hermans BP, Sweeney CJ, Foster RS et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumors managed by retroperitoneal lymph node dissection. J Urol 2000; 163: 1721-1724.
9. Sweeney CJ, Hermans BP, Heilman DK et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma- predominant testis cancer. J Clin Oncol 2000; 18: 358-362.
10. Freedman LS, Parkinson MC, Jones WG et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 2: 294-298.
11. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 1993; 23: 444-449.
12. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: a Medical Research Council report. J Clin Oncol 1996; 14: 441-448.
13. Klepp O, Dahl O, Flodgren P et al. Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 1997; 33: 1038-1044.
14. Pont J, Albrecht W, Postner, G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I non-seminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14: 441-448.
15. Chevreau CH, Mazerolles C, Soulie M et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004; 46: 209-215.
16. Sonneveld DJ, Schaffordt Koops H, Sleijfer DT, Hockstra HJ. Bilateral testicular germ cell tumours in patients with initial stage I disease: prevalence and prognosis - a single centre 30 years experience. Eur J Cancer 1998; 33: 244-252.